Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate the Effectiveness of SCENESSE as a Combination Treatment with NB-UVB Phototherapy in Vitiligo Patients with a Naturally Darker Skin Colour

Trial Profile

A Phase II Study to Evaluate the Effectiveness of SCENESSE as a Combination Treatment with NB-UVB Phototherapy in Vitiligo Patients with a Naturally Darker Skin Colour

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Vitiligo
  • Focus Registrational; Therapeutic Use
  • Sponsors Clinuvel Pharmaceuticals
  • Most Recent Events

    • 19 Dec 2018 Results of pooled analysis of all patients who received SCENESSE plus NB-UVB (n=18; randomized and open label parts) presented in a Clinuvel Pharmaceuticals media release.
    • 19 Dec 2018 According to a Clinuvel Pharmaceuticals media release, recruitment of patients of Asian origin who would accept temporary pandermal skin darkening during treatment was slow and the study design was modified from a randomised controlled (SCENESSE plus NB-UVB versus placebo plus NB-UVB) to an open label study (SCENESSE plus NB-UVB).
    • 19 Dec 2018 Status changed from active, no longer recruiting to completed, according to a Clinuvel Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top